Market Overview - The Hang Seng Index rose by 0.07%, gaining 19 points to close at 26,465 points, while the Hang Seng Tech Index increased by 0.39% [1] - Early trading volume in Hong Kong stocks reached HKD 160.2 billion [1] Notable Stock Movements - New pharmaceutical stocks in the Hong Kong Stock Connect surged, with Yaojie Ankang-B (02617) rising over 49%, reaching a market capitalization of over HKD 240 billion [1] - Baize Medical (02609) saw an increase of over 76% [1] - Tongyuan Kang Pharmaceutical-B (02410) rose by over 36% [1] Specific Company Highlights - Fosen Pharmaceutical (01652) experienced a dramatic rise of over 410%, closing at HKD 1.35, up 297%, following the approval of Metformin and Ertugliflozin tablets [2] - Shanghai Fudan (01385) increased by 5.87%, with the company prepared for supply chain disruptions, and Morgan Stanley noted limited impact on demand [2] - SF Express (09699) rose by over 6% as its "SoFast" service launched in Macau, with positive revenue growth prospects according to Daiwa [2] - Valiant Pharmaceuticals-B (09887) increased by over 13%, completing the first medication trial for its core product LBL-024 for melanoma [2] - Bilibili-W (09626) rose by 2.78%, accumulating a 25% increase over six days, with the new game "Three Kingdoms: Hundred Generals" set for testing in October [2] - Liontech Holdings (02562) surged over 7% as it plans to acquire a leading AI and blockchain company to expand its digital finance footprint [2] - GCL-Poly Energy (03800) rose by 3.97%, planning a discounted share placement to raise approximately HKD 5.392 billion for structural adjustments in polysilicon capacity [2] - CGN Mining (01164) increased by 6.7% amid expectations of rising uranium prices as the U.S. seeks to expand its strategic uranium reserves [2] - Yunfeng Financial (00376) fell over 16% after announcing a discounted share placement to raise about HKD 1.15 billion [2]

Group 1 - The stock of Hong Kong-based company, Tongyuan Kang Medical-B, surged over 40% in early trading on September 16, reaching a price of 21.36 HKD [1] - As of the report, the stock was up 37.9% with a trading volume of 1.664 billion HKD [1]

Core Viewpoint - Tongyuan Kang Pharmaceutical-B (02410) experienced a significant stock price increase of over 40%, attributed to the positive results of its innovative drug, Aditinib (TY-9591), in a key Phase II clinical trial for EGFR mutation advanced non-small cell lung cancer (NSCLC) [1][2] Group 1 - The stock price rose by 37.9% to HKD 21.36, with a trading volume of HKD 1.664 billion [1] - Aditinib's Phase II clinical trial results were selected for a Mini Oral presentation at the WCLC 2025 conference, highlighting its potential in treating NSCLC patients with EGFR mutations and brain metastases [1][2] - The trial involved 257 patients with EGFR mutation NSCLC and brain metastases, with a mid-term analysis showing an intracranial objective response rate (iORR) of 92.8% for Aditinib compared to 76.1% for Osimertinib, indicating significant efficacy [2]

Core Viewpoint - Tongyuan Kang Pharmaceutical-B (02410) experienced a significant stock price increase of over 40%, currently trading at 21.36 HKD, driven by the positive results of its innovative drug, Aiduotini (TY-9591), in a key Phase II clinical trial for EGFR mutation advanced non-small cell lung cancer (NSCLC) [1][2] Group 1: Clinical Trial Results - The key registration Phase II clinical trial (NCT05948813) for Aiduotini has been selected for a Mini Oral presentation at the WCLC 2025 conference, highlighting its importance in the medical community [1] - The trial is an open-label, multi-center, randomized controlled study focusing on NSCLC patients with EGFR mutations (L858R or 19Del) and brain metastases, comparing the efficacy and safety of Aiduotini (160mg once daily) against Osimertinib (80mg once daily) [1][2] - A total of 257 patients with EGFR mutation NSCLC and brain metastases were enrolled, with a mid-term analysis based on 224 patients showing an intracranial objective response rate (iORR) of 92.8% for the Aiduotini group compared to 76.1% for the Osimertinib group, with a statistically significant P-value of 0.0006 [2]

Core Insights - The article highlights the changes in the Hong Kong Stock Connect holdings, with notable increases and decreases in ownership percentages for various companies [1][2]. Group 1: Increased Holdings - Heng Rui Medicine (01276) saw the largest increase in ownership percentage, rising by 1.49% to a total of 13.84% [2]. - Kanglong Chemical (03759) experienced a 1.35% increase, bringing its ownership to 60.51% [2]. - Zhaoyan New Drug (06127) increased by 1.27%, reaching a holding of 43.70% [2]. - Other companies with significant increases include Junshi Biosciences (01877) at +1.24% (59.08%) and China Pacific Insurance (02601) at +1.20% (44.16%) [2]. Group 2: Decreased Holdings - Shandong Molong (00568) had the largest decrease, with a drop of 1.99% to 57.67% [2]. - Yisou Technology (02550) decreased by 0.99%, now holding 37.95% [2]. - Nanjing Panda Electronics (00553) saw a reduction of 0.98%, bringing its ownership to 42.65% [2]. - Other notable decreases include Kailai Ying (06821) at -0.95% (43.35%) and Meizhong Jiahe (02453) at -0.95% (32.06%) [2]. Group 3: Five-Day Changes - In the last five trading days, China Merchants Energy (01138) had the highest increase in ownership, up by 6.19% to 65.63% [3]. - Shandong Molong (00568) also saw a significant increase of 3.74% [3]. - Other companies with notable increases include Zhongchu Innovation (03931) at +3.62% (10.35%) and Youbao Online (02429) at +3.33% (17.38%) [3]. Group 4: Twenty-Day Changes - Over the past twenty days, Anjiren Food (02648) experienced the largest increase, up by 12.29% to 20.54% [4]. - China Merchants Energy (01138) also saw a significant increase of 9.07% [4]. - Other companies with notable increases include Yimai Sunshine (02522) at +7.70% (43.02%) and Lens Technology (06613) at +7.56% (13.64%) [4].

同源康医药-B(02410)发布公告，张森泉先生(张先生)已提出辞任本公司独立非执行董事(独立非执行董 事)以投放更多时间从事其他商业事务，自2025年9月15日起生效。辞任后，张先生不再担任董事会审计 委员会主席、董事会薪酬与考核委员会成员及提名委员会成员。 ...

智通财经APP讯，同源康医药-B(02410)发布公告，张森泉先生(张先生)已提出辞任本公司独立非执行董 事(独立非执行董事)以投放更多时间从事其他商业事务，自2025年9月15日起生效。辞任后，张先生不 再担任董事会审计委员会主席、董事会薪酬与考核委员会成员及提名委员会成员。 ...

格隆汇9月15日丨同源康医药-B(02410.HK)宣布，张森泉已提出辞任公司独立非执行董事以投放更多时 间从事其他商业事务，自2025年9月15日起生效。辞任后，张森泉不再担任董事会审计委员会主席、董 事会薪酬与考核委员会成员及提名委员会成员。 ...

TYK Medicines, Inc 浙江同源康醫藥股份有限公司 （於中華人民共和國註冊成立的股份有限公司） （股份代號：2410） 董事名單與其角色和職能 浙江同源康醫藥股份有限公司董事會（「董事會」）成員如下。 執行董事 董事會設立四個委員會。下表提供各董事會成員所在委員會的成員資料。 | | 委員會 | | 薪酬與考核 | | | | --- | --- | --- | --- | --- | --- | | 董事 | | 審計委員會 | 委員會 | 提名委員會 | 科學委員會 | | 吳豫生博士 | | | M | C | C | | 李鈞博士 | | M | | | M | | 顧虹博士 | | | | | | | 蔣鳴昱博士 | | | | | | | 何超先生 | | | | | | | 朱向陽博士 | | | | | | | 冷瑜婷博士 | | M | C | M | | | 許文青博士 | | | | | M | | 沈秀華博士 | | | | | | 附註： C 有關董事會委員會主席 吳豫生博士 非執行董事 李鈞博士 顧虹博士 蔣鳴昱博士 何超先生 朱向陽博士 獨立非執行董事 冷瑜婷博士 ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何意見，並明確表示概不就因本公告全部或任何部分內容而產生或因倚賴 該等內容而引致的任何損失承擔任何責任。 TYK Medicines, Inc 浙江同源康醫藥股份有限公司 （於中華人民共和國註冊成立的股份有限公司） （股份代號：2410） 獨立非執行董事辭任 及 暫未能符合相關上市規則 浙江同源康醫藥股份有限公司（「本公司」）董事（「董事」）會（「董事會」）宣佈，張 森泉先生（「張先生」）已提出辭任本公司獨立非執行董事（「獨立非執行董事」）以 投放更多時間從事其他商業事務，自2025年9月15日起生效。辭任後，張先生不 再擔任董事會審計委員會主席、董事會薪酬與考核委員會成員及提名委員會成 員。張先生已確認，彼與董事會及本公司之間並無意見分歧，亦概無有關其辭任 的事宜須提請本公司股東或香港聯合交易所有限公司（「聯交所」）垂注。 董事會謹藉此機會對張先生於其任職期間作出的寶貴貢獻致以衷心感謝。 董事長、執行董事兼總裁 吳豫生博士 香港，2025年9月15日 2 暫未能符合相關上市規則項下規定 張先生辭任後，本公司 ...